Lamivudine

• Lamivudine is an antiviral drug primarily used to treat HIV infection and chronic hepatitis B virus (HBV) infection.
• It functions as a nucleoside reverse transcriptase inhibitor (NRTI), blocking viral replication.
• Dosage varies significantly depending on the treated condition and patient characteristics.
• Common side effects are generally mild, but serious adverse reactions can occur, necessitating medical supervision.
• Regular monitoring is essential to assess treatment effectiveness and manage potential side effects.

What is Lamivudine?

Lamivudine is an antiviral medication classified as a nucleoside reverse transcriptase inhibitor (NRTI). It is a synthetic nucleoside analog that is phosphorylated intracellularly to its active 5′-triphosphate metabolite. This active form then competes with natural deoxycytidine triphosphate, inhibiting the activity of viral reverse transcriptase and DNA polymerase enzymes.

Its effectiveness against specific viruses, particularly human immunodeficiency virus (HIV) and hepatitis B virus (HBV), has made it a cornerstone in combination therapies. According to the World Health Organization (WHO), antiretroviral therapies, including lamivudine, have significantly reduced mortality and morbidity associated with HIV globally.

How Lamivudine Works

The mechanism of action for Lamivudine involves its incorporation into the growing viral DNA chain. Once incorporated, it acts as a chain terminator, preventing the addition of further nucleotides. This premature termination of the DNA chain effectively blocks the replication process of the virus. For HIV, it inhibits the enzyme reverse transcriptase, which is vital for converting viral RNA into DNA. For HBV, it inhibits the HBV DNA polymerase, an enzyme essential for viral replication. This targeted inhibition disrupts the viral life cycle, reducing the viral load in the body and slowing disease progression.

Lamivudine Uses and Dosage

Lamivudine is primarily used for the treatment of two major viral infections. It is a key component in highly active antiretroviral therapy (HAART) regimens for HIV-1 infection, typically used in combination with other antiretroviral drugs to prevent drug resistance and achieve maximum viral suppression. Additionally, it is prescribed for the management of chronic hepatitis B virus (HBV) infection, particularly in patients with evidence of active viral replication and persistent elevation of serum aminotransferases or histological evidence of active liver disease. Its ability to suppress viral load helps to reduce liver inflammation and prevent disease progression, such as cirrhosis and hepatocellular carcinoma.

Lamivudine dosage information is highly specific to the condition being treated and the patient’s renal function. For HIV infection, the typical adult dose is 150 mg twice daily or 300 mg once daily, always as part of a combination regimen. For chronic hepatitis B, the usual adult dose is 100 mg once daily. Doses must be adjusted for patients with impaired kidney function to prevent accumulation and potential toxicity. Pediatric dosages are calculated based on weight and body surface area. It is crucial for patients to adhere strictly to their prescribed dosage and schedule, as missing doses can lead to the development of drug resistance, particularly in HIV treatment.

Lamivudine Side Effects and Precautions

While generally well-tolerated, lamivudine side effects can occur. Most common side effects are mild and transient, often resolving as the body adjusts to the medication. However, some individuals may experience more significant adverse reactions. It is important to discuss any new or worsening symptoms with a healthcare provider.

Common side effects include:

• Headache
• Nausea and vomiting
• Diarrhea
• Abdominal pain
• Fatigue and malaise
• Insomnia

More serious, though less common, side effects can include pancreatitis, lactic acidosis (a rare but severe buildup of lactic acid in the blood), and severe hepatomegaly with steatosis (enlarged liver with fatty changes). Patients with pre-existing liver disease or those co-infected with HIV and HBV should be closely monitored. Discontinuation of lamivudine in HBV-infected patients can lead to a severe acute exacerbation of hepatitis B, requiring careful clinical and laboratory follow-up. Pregnant individuals should discuss the risks and benefits with their doctor, as lamivudine is generally considered safe for use during pregnancy, but careful monitoring is still advised.